Biolife solutions announces preliminary fourth quarter and full year 2023 unaudited revenue

Fourth quarter cell processing revenue increased 11% sequentially to $14.8 million bothell, wash. , jan. 8, 2024 /prnewswire/ -- biolife solutions, inc. (nasdaq: blfs) ("biolife" or the "company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (cgt) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue.
BLFS Ratings Summary
BLFS Quant Ranking